trending Market Intelligence /marketintelligence/en/news-insights/trending/lgc9mVvdCj5t6vnsgoyrCg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Australian drug development company Phylogica rebrands to PYC Therapeutics

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Australian drug development company Phylogica rebrands to PYC Therapeutics

Phylogica Ltd. changed its name to PYC Therapeutics Ltd. to reflect the company's shifted focus from drug discovery to drug development.

The name change will come into effect after the company gets shareholder approval at its annual general meeting scheduled for later in the year.

The Perth, Australia-based company has registered the new trading name with the Australian Securities and Investments Commission. It has also submitted a trademark application to IP Australia regarding the new name.

The rebranding is in line with the latest changes in the company's executive board and scientific board.

Phylogica is developing a pipeline of therapies for blinding eye diseases using its proprietary technology.